A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer

BMC Cancer

Hong-Yong Cao¹  Ai-Hua Yuan²  Wei Chen²  Xue-Song Shi²  Yi Miao¹ 

[1] Department of General Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China

[2] Department of General Surgery, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing, P. R. China

关键词: Live cell-SELEX;    In vivo imaging;    Molecular probe;    DNA aptamer;    Gastric cancer;   

Others  :  1121042
DOI  :  10.1186/1471-2407-14-699

 received in 2014-05-15, accepted in 2014-09-10,  发布年份 2014

【 摘 要 】

Background

Aptamers have emerged as excellent molecular probes for cancer diagnosis and therapy. The aim of the current study was to determine the feasibility of using DNA aptamer cy-apt 20 developed by live cell-SELEX for detecting and targeting gastric cancer.

Methods

The specificity, sensitivity and biostability of cy-apt 20 in detecting gastric cancer were assessed by binding assay, cell fluorescence imaging, and in vivo tumor imaging in animal model in comparison with non-gastric cancers.

Results

Flow cytometric analysis showed that cy-apt 20 had higher than 78% of maximal binding rate to gastric cancer cells, much higher than that of non-gastric cancer cells. Cell fluorescence imaging and in vivo tumor imaging showed that the targeting recognition could be visualized by using minimal dose of fluorochrome labeled cy-apt 20. Meanwhile, strong fluorescence signals were detected and lasted for a period of time longer than 50 min in vitro and 240 min in vivo. The fluorescence intensities of gastric cancer were about seven folds in vitro and five folds of that of non-gastric cancers in vivo.

Conclusion

Our study demonstrated that cy-apt 20 was an excellent molecular probe with high specificity and sensitivity and a certain degree of biostability for molecular recognition and targeting therapy of gastric cancer.

【 授权许可】

   
2014 Cao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M: A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 2013, 33(4):1257-1266.
• [2]Durães C, Almeida GM, Seruca R, Oliveira C, Carneiro F: Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014, 464:367-378.
• [3]Takahashi T, Saikawa Y, Kitagawa Y: Gastric cancer: current status of diagnosis and treatment. Cancer 2013, 5(1):48-63.
• [4]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [5]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr webcite
• [6]Jang BG, Kim WH: Molecular pathology of gastric carcinoma. Pathobiol 2011, 78(6):302-310.
• [7]Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N: Molecular pathology of gastric cancer: research and practice. Pathol Res Pract 2011, 207(10):608-612.
• [8]Ding SZ, Goldberg JB, Hatakeyama M: Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol 2010, 6(5):851-862.
• [9]Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N: Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014, 50(7):1330-1344.
• [10]Diamandis EP: Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010, 102(19):1462-1467.
• [11]Almendro V, Marusyk A, Polyak K: Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013, 24(8):277-302.
• [12]Kern SE: Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012, 72(23):6097-6101.
• [13]Pavlou MP, Diamandis EP, Blasutig IM: The long journey of cancer biomarkers from the bench to the clinic. Clin Chem 2013, 59(1):147-157.
• [14]Lassalle HP, Marchal S, Guillemin F, Reinhard A, Bezdetnaya L: Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. Curr Drug Metab 2012, 13(8):1130-1144.
• [15]Radom F, Jurek PM, Mazurek MP, Otlewski J, Jeleń F: Aptamers: molecules of great potential. Biotechnol Adv 2013, 31(8):1260-1274.
• [16]Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249(4968):505-510.
• [17]Stoltenburg R, Reinemann C, Strehlitz B: SELEX-a (r) evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007, 24(4):381-403.
• [18]Hermann T, Patel DJ: Adaptive recognition by nucleic acid aptamers. Science 2000, 287(5454):820-825.
• [19]Sefah K, Shangguan D, Xiong X, O’Donoghue MB, Tan W: Development of DNA aptamers using Cell-SELEX. Nat Protoc 2010, 5(6):1169-1185.
• [20]Zhu G, Ye M, Donovan MJ, Song E, Zhao Z, Tan W: Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb) 2012, 48(85):10472-10480.
• [21]Cerchia L, de Franciscis V: Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 2010, 28(10):517-525.
• [22]Zhang Y, Chen Y, Han D, Ocsoy I, Tan W: Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2010, 2(5):907-918.
• [23]Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W: Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103(32):11838-11843.
• [24]Sefah K, Tang ZW, Shangguan DH, Chen H, Lopez-Colon D, Li Y, Parekh P, Martin J, Meng L, Phillips JA, Kim YM, Tan WH: Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 2009, 23(2):235-244.
• [25]Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M, Sun W, Goodison S, Tan W: Novel aptamer developed for breast cancer cell internalization. ChemMedChem 2012, 7(1):79-84.
• [26]Kunii T, Ogura S, Mie M, Kobatake E: Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst 2011, 136(7):1310-1312.
• [27]Sefah K, Meng L, Lopez-Colon D, Jimenez E, Liu C, Tan W: DNA aptamers as molecular probes for colorectal cancer study. PLoS One 2010, 5(12):e14269.
• [28]Sefah K, Bae KM, Phillips JA, Siemann DW, Su Z, McClellan S, Vieweg J, Tan W: Cell-based selection provides novel molecular probes for cancer stem cells. Int J Cancer 2013, 132(11):2578-2588.
• [29]Zueva E, Rubio LI, Ducongé F, Tavitian B: Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion. Int J Cancer 2011, 128(4):797-804.
• [30]Hu M, Zhang K: The application of aptamers in cancer research: an up-to-date review. Future Oncol 2013, 9(3):369-376.
• [31]Xing H, Hwang K, Li J, Torabi SF, Lu Y: DNA aptamer technology for personalized medicine. Curr Opin Chem Eng 2014, 5(4):79-87.